Sun Pharma unit gets USFDA approval for generic Namenda
India's Sun Pharmaceutical Industries Limited today said its subsidiary had received a tentative approval from the United States Food and Drugs Administration to market a generic version of Forest Laboratories, Inc.'s Namenda 5 mg and 10 mg tablets.
A press release from Sun Pharma said these generic Memantine tablets were equivalent to Forest Laboratories' Namenda tablets and included two strengths: 5 mg and 10 mg. These strengths of Memantine have a combined annual sale of approximately $1.2 billion in the US.
According to the release, Memantine tablets are indicated for the treatment of moderate to severe Alzheimer's disease.
April 27, 2010